Home > Journals > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Past Issues > Gazzetta Medica Italiana Archivio per le Scienze Mediche 2000 October;159(5) > Gazzetta Medica Italiana Archivio per le Scienze Mediche 2000 October;159(5):159-63

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

REVIEWS   

Gazzetta Medica Italiana Archivio per le Scienze Mediche 2000 October;159(5):159-63

Copyright © 2000 EDIZIONI MINERVA MEDICA

language: Italian

Marshall’s syndrome. A new periodic fever

Cau C.

DEA - dell’Azienda ospedaliera S. Giovanni Addolorata - Roma


PDF


A syn­drome of peri­odic ­fever has ­been iden­ti­fied ­recently by Mar­shall in 12 chil­dren ­observed at two ­major ­referral cen­ters. The ­acronym ­used to ­describe the syn­drome is ­PFAPA (for ­fever, aph­thosis, sto­ma­titis, pha­ryn­gitis and cer­vical ade­nitis). ­Attacks char­ac­ter­ized by ­abrupt ­onset of ­fever, mal­aise, ­chills, aph­tosis, sto­ma­titis, pha­ryn­gitis, hed­ache and ­tender cer­vical ade­nop­athy ­occur at 4- to 6 ­week inter­vals ­over ­periods of ­years. ­These epi­sodes of ill­ness ­resolve spon­ta­ne­ously in 4 to 5 day. ­Mild leu­ko­cy­tosis and ele­va­tion of the eryth­ro­cyte sed­i­men­ta­tion ­rate ­during ­attacks are the ­only labor­a­tory abnor­mal­ities. ­Affected chil­dren ­grow nor­mally. In ­some chil­dren the syn­drome ­resolves, ­whereas symp­toms fn ­others per­sist for ­years and com­pli­ca­tions ­have not ­been ­described. A ­number of ­other syn­dromes char­ac­ter­ized by recur­rent ­fever ­have ­been ­reported and com­pared ­with ­PFAPA: ­familial Med­i­ter­ra­nean ­fever, the ­hyper-IgD syn­drome, ­Behçet dis­ease, hered­i­tary angioe­dema, ­cyclic neu­tro­penia, ­familial Hiber­nian ­fever. ­Attacks may ­aborted by ­short ­courses of pred­ni­sone but do not ­respond to non ster­oidal ­anti-inflam­ma­tory ­agents. Ace­tam­i­no­phen and anti­bi­otic ­drugs ­were ­reported to ­have ­modest ther­a­peutic ben­efit Cimet­i­dine was sug­gested as a pro­phy­lactic treat­ment for ­PFAPA in 1992. It ­appeared to be ­highly effec­tive in pre­venting ­attacks in ­some ­patients. How­ever, we ­cannot ­explain why, ­when cimet­i­dine was dis­con­tinued, ­PFAPA syn­drome did not ­recur. Per­haps a per­ma­nent ­change in ­these ­patients’ ­immune ­systems fol­lowed the 6 to 8 ­months of cimet­i­dine ­therapy. ­Another pos­sibility is spon­ta­neous remis­sion.

top of page